G007-LK Tankyrase 1/2 Inhibitor: Precision Tools in Cancer Research

Principle and Setup: Targeting Tankyrase for Pathway Disruption

The G007-LK tankyrase 1/2 inhibitor is a potent, small-molecule tool developed for the selective inhibition of tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), two members of the poly(ADP-ribosyl) polymerase family integral to cell signaling and structural regulation. By arresting tankyrase-mediated poly(ADP-ribosyl)ation, G007-LK enables precise modulation of the Wnt/β-catenin signaling pathway, a cascade fundamentally linked to cell proliferation, tissue homeostasis, and cancer progression. The inhibitor’s nanomolar IC50 values of 46 nM (TNKS1) and 25 nM (TNKS2) underscore its biochemical specificity and suitability for dissecting tankyrase-dependent processes [source_type: product_spec][source_link: https://www.apexbt.com/g007-lk.html].

In research models, including HEK 293 cells and APC-mutant colorectal cancer lines (SW480), G007-LK has been shown to induce β-catenin degradation and suppress Wnt signaling with cell-based IC50s as low as 0.05 μM [source_type: product_spec][source_link: https://www.apexbt.com/g007-lk.html]. This positions the compound at the forefront of functional studies aimed at elucidating the roles of tankyrase in oncogenesis and pathway crosstalk. APExBIO, the trusted supplier behind G007-LK, ensures consistent quality and experimental reproducibility for advanced cancer research workflows.

Step-by-Step Experimental Workflow and Protocol Enhancements

The operationalization of G007-LK in the lab hinges on rigorous solubilization, dosing, and timing parameters. Its robust solubility profile (≥26.5 mg/mL in DMSO) allows for the preparation of concentrated stocks, which can be readily diluted into assay media for both in vitro and in vivo applications [source_type: product_spec][source_link: https://www.apexbt.com/g007-lk.html]. Researchers typically employ G007-LK for:

• Wnt/β-catenin reporter assays to quantify pathway inhibition
• Western blot or immunofluorescence to monitor β-catenin, AXIN1/2, TNKS1/2, and YAP/AMOTL1/2 levels
• Colony formation and cell proliferation assays in tumor models
• In vivo xenograft studies to evaluate tumor growth suppression

Workflow flexibility is a hallmark of G007-LK, facilitating adaptation across 2D cell culture, spheroid, and animal model settings. The compound’s low off-target activity ensures that observed phenotypes are primarily attributed to tankyrase inhibition, minimizing confounding variables when interpreting Wnt/β-catenin and Hippo pathway readouts.

Protocol Parameters

• Cellular Wnt reporter assay | 0.05 μM (final concentration) | HEK 293 or SW480 cells | Achieves robust inhibition of Wnt3a-induced luciferase activity | product_spec (URL)
• In vivo xenograft dosing | 20–40 mg/kg (once daily, oral gavage) | COLO-320DM colorectal cancer mouse models | Produces significant tumor growth inhibition and target protein modulation | product_spec (URL)
• Stock preparation | Dissolve at ≥26.5 mg/mL in DMSO; store at -20°C | All in vitro/in vivo applications | Ensures maximal solubility and compound integrity for short-term experimental use | product_spec (URL)

Key Innovation from the Reference Study

In the pivotal study by Jia et al. (2017), G007-LK was systematically compared to XAV-939 in hepatocellular carcinoma (HCC) models to dissect its impact on cell proliferation and Hippo pathway regulation. The authors demonstrated that G007-LK not only suppressed HCC cell growth in a dose-dependent manner but also downregulated YAP protein levels and TEAD reporter activity, while stabilizing AMOTL1/2 proteins—key negative regulators of YAP [source_type: paper][source_link: https://doi.org/10.1371/journal.pone.0184068]. This mechanistic insight translates into practical guidance: when designing proliferation or reporter assays in cancer models, simultaneous monitoring of both Wnt/β-catenin and Hippo/YAP pathway markers is essential to fully capture the spectrum of tankyrase inhibitor effects.

Advanced Applications and Comparative Advantages

G007-LK’s utility extends beyond standard Wnt pathway interrogation. In APC-mutated colorectal cancer research, the compound’s ability to induce dynamic degradasome formation (β-catenin, β-TrCP, ubiquitin) and reduce nuclear β-catenin levels underpins its value in mechanistic and translational oncology studies [source_type: product_spec][source_link: https://www.apexbt.com/g007-lk.html]. In vivo, G007-LK achieves reliable colorectal tumor growth suppression at 20–40 mg/kg, accompanied by reduction in TNKS1/2 and β-catenin, and stabilization of AXIN1/2 [source_type: product_spec][source_link: https://www.apexbt.com/g007-lk.html].

Researchers can also leverage G007-LK for synergy studies. As highlighted by Jia et al., combining tankyrase inhibitors with MEK or AKT inhibitors yielded enhanced suppression of HCC proliferation [source_type: paper][source_link: https://doi.org/10.1371/journal.pone.0184068]. This positions G007-LK as a strategic component in multi-pathway targeting regimens and functional genomics screens.

For further context, the article "G007-LK Tankyrase 1/2 Inhibitor: Unraveling Wnt/β-Catenin..." complements these findings by detailing how G007-LK enables deep interrogation of Wnt/β-catenin and Hippo pathway interactions in APC mutation-driven colorectal cancer. Meanwhile, "Strategic Dissection of G007-LK: Precision Tankyrase 1/2 ..." extends the discussion to competitive research landscapes and emerging translational use-cases, making these resources valuable for researchers designing cross-model experiments.

Troubleshooting and Optimization Tips

• Solubility Management: G007-LK is insoluble in water and ethanol; always dissolve in DMSO at recommended concentrations and avoid aqueous pre-dilution to prevent precipitation [source_type: product_spec][source_link: https://www.apexbt.com/g007-lk.html].
• Cell Line Sensitivity: APC-mutant versus wild-type colorectal cancer lines may exhibit different responsiveness. Titrate G007-LK concentrations and monitor β-catenin and AXIN1/2 stabilization to determine optimal dosing [source_type: workflow_recommendation].
• In Vivo Formulation: For animal studies, immediately prepare fresh dosing solutions and limit DMSO content to ≤10% to minimize toxicity. Consider vehicle controls and monitor for compound precipitation over time [source_type: workflow_recommendation].
• Cross-pathway Readout: For assays exploring Hippo pathway crosstalk, ensure inclusion of YAP, AMOTL1/2, and TEAD reporter assays in parallel with Wnt/β-catenin endpoints [source_type: paper][source_link: https://doi.org/10.1371/journal.pone.0184068].
• Stability: Store both powder and DMSO stocks at -20°C. Avoid repeated freeze-thaws; use aliquots for short-term experiments [source_type: product_spec][source_link: https://www.apexbt.com/g007-lk.html].

Future Outlook: Translational Implications and Evolving Applications

The growing body of evidence, anchored by Jia et al. and reinforced by translational commentaries such as "Translating Tankyrase Inhibition Into Precision Oncology:...", forecasts a promising future for tankyrase inhibitors like G007-LK in cancer research. As the mechanistic links between Wnt/β-catenin and Hippo/YAP signaling become clearer, G007-LK will remain central to dissecting these intersecting networks, particularly in APC mutation colorectal cancer and hepatocellular carcinoma models [source_type: paper][source_link: https://doi.org/10.1371/journal.pone.0184068]. Continued protocol refinements and combinatorial studies will likely enhance the translational impact of this molecule, paving the way for novel pathway-targeted therapeutic strategies.

For researchers seeking validated, high-performance reagents, APExBIO’s G007-LK tankyrase 1/2 inhibitor is a benchmark tool for pathway modulation, β-catenin degradation induction, and colorectal tumor growth suppression in both in vitro and in vivo settings.